Zunsemetinib ATI-450; CDD-450|cas:1640282-42-3|西域试剂

Zunsemetinib ATI-450; CDD-450,99.37%

产品编号：Bellancom-139553| CAS NO：1640282-42-3| 分子式：C₂₅H₂₂ClF₂N₅O₃| 分子量：513.92

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-139553		￥8500.00	杭州北京（现货）
Bellancom-139553		￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Zunsemetinib ATI-450; CDD-450

产品介绍

Zunsemetinib (CDD-450) 是一种具有口服活性的 p38α 丝裂原激活蛋白激酶激活蛋白激酶2 (MK2)通路抑制剂。Zunsemetinib 可用于免疫炎症性疾病的研究。

生物活性

Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.

体外研究

Zunsemetinib (1 and 10 μM; 1 hour; WT and NOM ID BMMs) has no effect on NLRP3 expression, but decreases IL-1β expression by promoting IL-1β mRNA degradation.
Zunsemetinib (0.4 nM~1 μM; 16 hours; PBMC) reduces IL-1β secretion and promotes IL-1β mRNA instability.
Zunsemetinib selectively blocks p38α MAPK activation of the proinflammatory kinase MK2 while sparing p38α activation of other effectors such as PRAK and ATF2. Zunsemetinib inhibits in vitro osteoclast formation induced by RANKL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	WT and NOM ID BMMs
Concentration:	1 and 10 μM
Incubation Time:	1 hour
Result:	Had no effect on NLRP3 expression, but decreased IL-1β expression by promoting IL-1β mRNA degradation.

体内研究
(In Vivo)

Zunsemetinib (1,000 ppm; p.o.) blocks LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.
Zunsemetinib (10 and 20 mg/kg; p.o.) increases bone density.
Zunsemetinib prevents osteopenia in NOM ID^c mice through inhibition of osteoclastogenesis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old WT female mice
Dosage:	1,000 ppm
Administration:	P.o.
Result:	Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.

Animal Model:	Rats
Dosage:	10 and 20 mg/kg
Administration:	P.o.
Result:	Increased bone density.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old WT female mice
Dosage:	1,000 ppm
Administration:	P.o.
Result:	Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.

Animal Model:	Rats
Dosage:	10 and 20 mg/kg
Administration:	P.o.
Result:	Increased bone density.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-week-old WT female mice
Dosage:	1,000 ppm
Administration:	P.o.
Result:	Blocked LPS-induced TNF-α expression persisted for up to 4 weeks after dosing.

Animal Model:	Rats
Dosage:	10 and 20 mg/kg
Administration:	P.o.
Result:	Increased bone density.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (194.58 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9458 mL	9.7291 mL	19.4583 mL
5 mM	0.3892 mL	1.9458 mL	3.8917 mL
10 mM	0.1946 mL	0.9729 mL	1.9458 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式